News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cytokinetics, Inc. (CYTK) Says 58 in ALS Trial Got Placebo in Error


7/8/2013 8:15:51 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cytokinetics Inc. (CYTK) is evaluating the costs and timing of a clinical trial for its amyotrophic lateral sclerosis treatment after some patients were given a placebo by mistake. The shares fell as much as 8.8 percent. Fifty-eight patients slated to receive the drug, called tirasemtiv, were instead given the placebo due to a computer programming error, the South San Francisco, California-based company said in a statement today. The error has been fixed and the trial is continuing, Cytokinetics said. No participants assigned to the control group were given the treatment. Tirasemtiv treats amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease, a fatal breakdown of the central nervous system with no known cure. The trial, designed to enroll as many as 500 patients, was in the second of three stages usually required to win marketing approval in the U.S.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Street Insider
Read at Seeking Alpha
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES